Screener / SEC EDGAR /CIK 0001232524 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Jazz Pharmaceuticals plc JAZZ

Compare with peers Embed
The 10-K against last year's

295 changes: 56 added, 43 removed, 185 reworded, 11 quiet changes

10-K Feb 24, 2026 vs Feb 26, 2025

10-K 0001232524-26-000013 (Feb 24, 2026) vs 10-K 0001232524-25-000011 (Feb 26, 2025) Not compared: Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

280 paragraphs · 23 new · 111 reworded · 8 gone · 10-K Feb 24, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 84 · 49% changed Every version of it
In part due While we cannot at this time predict the ultimate impact of such tariffs, we anticipate that our margins could be adversely affected beginning as early as fiscal 2026, depending on the ultimate scope and duration of tariffs imposed. Additionally, it is possible that such tariffs could affect imports of APIs and other raw materials used in our products, or our business may be adversely impacted by retaliatory trade measures taken by other countries, including restricted access to APIs or other raw materials used in our products, further disrupting our supply chain and increasing our costs. Given the limited market size for our products and product candidates, we have a single source of supply for most nature of our marketed products, product candidates and their APIs. Single sourcing puts us at risk of interruption in relocating the manufacturing supply in the event of manufacturing, quality or compliance difficulties. If one of our suppliers fails or refuses response to supply tariffs and other trade restrictions would be a complex, costly and time-consuming process making it difficult for us for any reason, to react quickly to a rapidly changing environment. In this regard, it would take a significant amount of time and expense to implement and execute the necessary technology transfer to, and to qualify, a new supplier. FDA and similar international or national regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in suppliers for our products. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA’s or similar international regulatory body’s requirements for approval, there could be a shortage of the affected products for the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need. revenues.
Paragraph 253 · 47% changed Every version of it
One example is the OECD’s initiative in the area of “base erosion and profit shifting.” In October 2021, shifting,” including the OECD released Pillar Two. In December 2022, the EU agreed to implement this 15% global minimum tax rate for EU member states by the start of 2024. In accordance with the EU directive, under Pillar Two. Ireland adopted legislation implementing Pillar Two on December 18, 2023, with effect from the start beginning of 2024. Other 2024, and a number of other jurisdictions in which we do business have also adopted legislation implementing certain key aspects of Pillar Two. Two, with further provisions expected to be enacted in the future. The OECD has issued (and is expected to continue to issue further) administrative guidance providing transition and safe harbor rules in relation to the implementation of the Pillar Two proposal. For example, on January 5, 2026, the OECD published a package of administrative guidance providing for, among other things, the extension of the application of certain existing transitional safe harbor rules and the introduction of additional safe harbors. We are monitoring developments and evaluating the potential impacts of the Pillar Two rules, including on our effective tax rates, and considering our eligibility to qualify for the relevant safe harbor rules. Any further Pillar Two legislation or guidance could have an adverse impact on our effective tax rate, tax liabilities, and cash tax. tax and may increase our compliance costs.
Paragraph 249 · 47% changed Every version of it
We are subject to reviews and audits by the U.S. IRS, and other taxing authorities from time to time, and the IRS or other taxing authority may challenge our structure, transfer pricing arrangements and tax positions through an audit or lawsuit. Responding to or defending against challenges from taxing authorities could be expensive and consume time and other resources. If we are unsuccessful, we may be required to pay additional taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could require us to reduce our operating expenses, decrease efforts in support of our products or seek to raise additional funds. Any of these actions could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Paragraph 129 · 46% changed Every version of it
We have settled patent litigation with each of the ten companies seeking to introduce market a generic versions version of Xyrem Epidiolex in the U.S. by granting those companies licenses each of the Epidiolex ANDA Filers a license to launch their manufacture, market, and sell its own generic products (and in certain cases, an AG version of Xyrem) Epidiolex beginning in advance the very late 2030s, or earlier under certain circumstances, including but not limited to the launch of another generic Epidiolex product or a final decision that all unexpired claims of the expiration of the last of our patents. Epidiolex patents are not infringed, or are invalid and/or unenforceable. Notwithstanding our Xyrem patents listed in FDA’s Orange Book for Epidiolex and settlement agreements, additional third parties may also attempt to introduce generic versions of Xyrem, Xywav or other sodium oxybate products for treatment of cataplexy and/or EDS in narcolepsy Epidiolex that design around our patents or assert that our patents are invalid or otherwise unenforceable. Such third parties could launch a generic or 505(b)(2) product referencing Xyrem before the dates provided in our patents or settlement agreements. For example, we have several methods of use patents listed in the Orange Book, that expire in 2033 that cover treatment methods included in the Xyrem label related to a DDI with divalproex sodium. Although FDA has stated, in granting a Citizen Petition we submitted in 2016, that it would not approve any sodium oxybate ANDA referencing Xyrem that does not include the portions of the currently approved Xyrem label related to the DDI patents, we
Paragraph 44 · 45% changed Every version of it
Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental changes, particularly given the current atmosphere of mounting criticism of prescription drug costs in the U.S. We expect there will continue to be legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products profitably, as governmental oversight and scrutiny of biopharmaceutical companies is increasing. For example, we anticipate that the U.S. Congress, state legislatures, and federal and state regulators may adopt or accelerate adoption of new healthcare policies and reforms intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare, Medicaid and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs, and additional pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures. This includes efforts by individual states in the U.S. to pass legislation and implement regulations designed to control pharmaceutical and biological product pricing, including by establishing Prescription Drug Affordability Boards (or similar entities) to review high-cost drugs and, in some cases, set upper payment limits and implementing marketing cost disclosure and transparency measures. Further, the IRA, among other things, requires the U.S. Department of Health and Human Services Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, which could negatively affect our business and financial condition. The CMS has issued final guidance implementing the Drug Price Negotiation Program in which it finalized certain policies governing the selection of drugs for negotiation. Among other things, CMS finalized definitions of “qualifying single source drug” and “marketed” that, especially if they persist, could further disincentivize innovation. In addition, under the Medicaid Drug Rebate Program, rebates owed by manufacturers are no longer subject to a cap on the rebate amount effective January 1, 2024, which may adversely affect our rebate liability.
Paragraph 45 · 44% changed Every version of it
Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental changes, particularly given the current atmosphere of mounting criticism of prescription drug costs in the U.S. We expect there will continue to be legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products profitably, as governmental oversight and scrutiny of biopharmaceutical companies is increasing. For example, we anticipate that the U.S. Congress, state legislatures, and federal and state regulators may adopt or accelerate adoption of new healthcare policies and reforms intended to curb healthcare costs, such as federal and state controls on reimbursement for drugs (including under Medicare, Medicaid and commercial health plans), new or increased requirements to pay prescription drug rebates and penalties to government health care programs, and additional pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures. In addition, policymakers and federal agencies, including the Center for Medicare & Medicaid Innovation, are advancing new drug pricing models to implement MFN reference pricing, which has been a focus of the Trump Administration’s health policy agenda. These initiatives, if finalized and implemented, could reduce the net prices for certain products, exert downward pricing pressure, and adversely affect our revenues and profitability. This includes efforts by individual states in the U.S. to pass legislation and implement regulations designed to control pharmaceutical and biological product pricing, including by establishing Prescription Drug Affordability Boards (or similar entities) to review high-cost drugs and, in some cases, set upper payment limits and implementing marketing cost disclosure and transparency measures. Further, the IRA, among other things, requires the U.S. Department of Health HHS imposes rebates on many Medicare Part B and Human Services Secretary Medicare Part D products to negotiate, with respect penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to Medicare units and subject to a specified cap, negotiate the price of a set number certain single-source drugs that have been on the market for at least 7 years covered under Medicare as part of certain high the Medicare spend drugs and biologicals per Drug Price Negotiation Program. Each year starting in 2026, penalizes manufacturers of certain up to twenty (20) products will be selected by HHS for the Medicare Parts B and D drugs for price increases above inflation, and makes several changes Drug Price Negotiation Program. Products subject to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, which could negatively affect our business and financial condition. The CMS has issued final guidance implementing the Drug Price Negotiation Program are expected to experience a significant reduction in which it finalized certain policies governing reimbursement from the selection of drugs for negotiation. Among other things, CMS finalized definitions of “qualifying single source drug” and “marketed” that, especially if they persist, could further disincentivize innovation. Medicare program on a per unit basis. In addition, under the Medicaid Drug Rebate Program, rebates owed by manufacturers are no longer subject to a cap on the rebate amount effective January 1, 2024, which may adversely affect our rebate liability. The foregoing may negatively impact our overall rebate and discount liability, which would have a negative adverse effect on our revenues.
Paragraph 255 · 43% changed Every version of it
The U.S. and other jurisdictions in which we operate continue to consider other changes in tax laws and regulations that apply to multinationals, including proposed legislation and guidance with respect to research and development R&D expenditures and other guidance under the 2017 Tax Cuts and Jobs Act. The new presidential administration has included as part On July 4, 2025, the U.S. adopted legislation that extended certain provisions of its agenda a potential reform of U.S. tax laws, the details of which have not yet emerged. In addition, certain of the provisions in the 2017 Tax Cuts and Jobs Act will change or expire Act, which would otherwise have expired on December 31, 2025 unless Congress takes action 2025, and introduced a number of other changes to extend these provisions in their current form. In particular, a significant portion of our income taxable in the U.S. qualifies for preferential treatment as foreign-derived intangible income. Beginning in 2026, the effective tax rate for foreign-derived intangible income will increase from 13% to 16%. If U.S. tax rates increase and/or laws, including immediate expensing of domestic research and experimentation expenditures. The new legislation also introduced certain amendments to the foreign-derived intangible income deduction is reduced or eliminated, provisions, with effect as of 2026. We are still evaluating the effect of the new legislation on our tax provision, cash tax liability and effective tax rate would be adversely affected. rate.
Paragraph 103 · 42% changed Every version of it
As a result of these or other factors, products or product candidates we acquire, or obtain licenses to, may not produce the revenues, earnings or business synergies that we anticipated, may not result in regulatory approvals, and may not perform as expected. For example, in May 2021, we made a substantial investment in Epidiolex and certain other products and technologies acquired in our acquisition of GW. The total consideration paid by us for the entire issued share capital of GW was $7.2 billion. The success of our acquisition of GW will depend, in part, on our ability to realize the anticipated benefits from the acquisition, which benefits may not be realized at the expected levels within the expected timeframe, or at all, or may

MD&A

189 paragraphs · 33 new · 89 reworded · 35 gone · 10-K Feb 24, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 38 · 49% changed
In April 2022, August 2025, we announced that we had entered into a licensing and collaboration global license agreement with Werewolf Saniona to acquire obtain exclusive global development and commercialization worldwide rights to Werewolf's investigational WTX-613, develop SAN2355, now referred to as JZP898. JZP053, for epilepsy and other potential indications. JZP053 is a preclinical, selective small molecule activator of Kv7.2/Kv7.3 potassium channels, a mechanism validated for seizure suppression. Under the terms of the agreement, we made an upfront payment to Saniona of $15.0 million to Werewolf, and Werewolf $42.5 million. Saniona is eligible to receive development, up to $192.5 million in development and regulatory and milestones, up to $800 million in commercial milestone payments of up and tiered royalties ranging from mid-single digits to $1.26 billion. If approved, Werewolf is eligible to receive a tiered, mid-single-digit percentage royalty low-double digits on net sales of JZP898. commercial products resulting from the development of JZP053. This transaction underscores further expands our commitment to enhancing early-stage neuroscience pipeline building on our pipeline to deliver novel oncology therapies to patients, and also provides us with an opportunity to expand into immuno-oncology. JZP898 is a differentiated, conditionally-activated IFNα INDUKINE™ molecule. We initiated a Phase 1 clinical trial existing expertise in the treatment of JZP898 in late 2023. epilepsy.
Paragraph 90 · 49% changed
We expect product sales, net will total revenues in 2026 to increase in 2025 over 2024, primarily compared to 2025, driven by continued growth across in our commercial portfolio, rare oncology and epilepsy products including Modeyso, Ziihera and Epidiolex/Epidyolex, offset by a decrease reduction in sales of Xyrem oxybate revenues due to decreased high-sodium AG royalties and Xyrem revenues following the impact launch of multiple generic high-sodium oxybate competition. products.
Paragraph 8 · 48% changed
Product Indications Initial Approval Date Markets Rylaze® (asparaginase erwinia chrysanthemi (recombinant)- A component of a multi-agent chemotherapeutic regimen for the treatment of ALL, and LBL, in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. June 2021 U.S. rywn) Rylaze® (crisantaspase recombinant) A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL, in adults and pediatric patients 1 year or older who have developed hypersensitivity to September 2022 Canada E. coli-derived asparaginase. Enrylaze® (recombinant crisantaspase) A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL in adult and pediatric patients (1 month and older) who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. September 2023 EU, Great Britain, Switzerland, other markets Zepzelca® (lurbinectedin) Treatment of adult patients with metastatic SCLC, with disease progression on or after platinum-based chemotherapy. June 2020 U.S. (licensed from PharmaMar)2 Treatment of adults with Stage III or metastatic SCLC who have progressed on or after platinum-containing therapy. September 2021 Canada (licensed from PharmaMar)3 Ziihera® (zanidatamab-hrii) Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test. November 2024 U.S. (licensed from Zymeworks)2
Paragraph 33 · 47% changed
benefit when administered as second-line SCLC therapy. Results from the Phase 4 observational trial were presented at the 2025 WCLC that showed Zepzelca demonstrated clinically meaningful effectiveness across subgroups, including those with platinum-resistant disease and those with CNS metastases. The safety and tolerability profile observed in this Phase 4 study was consistent with prior findings, with no new safety signals reported.
Paragraph 107 · 46% changed
To continue to grow our business over the longer term, we plan to commit substantial resources to product acquisition and in-licensing, product development, clinical trials of product candidates and expansion of our commercial, development, manufacturing and other operations. In this regard, we have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our strategy to acquire or in-license and develop additional products and product candidates. Acquisition opportunities that we pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. We regularly evaluate the performance of our products and product candidates to ensure fit within our portfolio and support efficient allocation of capital. In addition, we may pursue new operations or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. Raising additional capital could be accomplished through one or more public or private debt or equity financings, collaborations or partnering arrangements. However, our ability to raise additional capital may be adversely impacted by worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of inflationary pressures, potential future bank failures, or otherwise. Accordingly, we could experience an inability to access additional capital or our liquidity could otherwise be impacted, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, under Irish law we must have authority from our shareholders to issue any ordinary shares, including ordinary shares that are part of our authorized but unissued share capital, and we currently have such authorization. Moreover, as a matter of Irish law, when an Irish public limited company issues ordinary shares to new shareholders for cash, the company must first offer those shares on the same or more favorable terms to existing shareholders on a pro rata basis, unless this statutory pre-emption obligation is dis-applied, or opted-out of, by approval of its shareholders. At our annual general meeting of shareholders in July 2024, our shareholders voted to approve our proposal to dis-apply the statutory pre-emption obligation. This current pre-emption opt-out authority is due to expire in January 2026. If we are unable to obtain further pre-emption authorities from our shareholders in the future, or otherwise continue to be limited by the terms of new pre-emption authorities approved by our shareholders in the future, our ability to use our unissued share capital to fund in-licensing, acquisition or other business opportunities, or to otherwise raise capital, including at the time we are required to make repurchases of the 2026 Notes, the 2030 Notes and/or the Secured Notes, are required to repay outstanding amounts under the Amended Credit Agreement, or pay cash upon exchange of the 2026 Notes or the 2030 Notes, could likewise be adversely affected. affected or precluded altogether. In any event, an inability to borrow or raise additional capital in a timely manner and on attractive terms could prevent us from expanding our business or taking advantage of acquisition opportunities and could otherwise have a material adverse effect on our business and growth prospects. In addition, if we use a substantial amount of our funds to acquire or in-license products or product candidates, we may not have sufficient additional funds to conduct all of our operations in the manner we would otherwise choose. Furthermore, any equity financing would be dilutive to our shareholders, and could require the consent of the lenders under the Amended Credit Agreement that provides for (i) the Tranche B-2 Dollar Term Loans and Amended Revolving Credit Facility, and the indenture for the Secured Notes for certain financings.
Paragraph 28 · 46% changed
•Following Following positive data from a pivotal Phase 2b 2 clinical trial evaluating zanidatamab monotherapy in patients with previously treated advance advanced or metastatic HER2-amplified BTC, we completed a BLA submission in second-line BTC in March 2024. This In May 2024, FDA granted priority review of the BLA; we received FDA accelerated approval for this BLA received Priority Review, and zanidatamab was approved by FDA under the trade name Ziihera in November 2024. In April 2025, we announced that CHMP adopted a positive opinion recommending the conditional marketing authorization of zanidatamab in second-line BTC. In June 2025, the EC granted conditional marketing authorization for Ziihera for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC previously treated with at least one prior line of systemic therapy. In January 2026, Ziihera obtained conditional approval in Canada for the treatment of adults with previously treated, unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC, as monotherapy.
Paragraph 64 · 44% changed
•Announced positive top-line findings results from the Phase 3 IMforte HERIZON-GEA-01 trial, showing statistically significant and clinically meaningful progression-free survival and overall survival benefits for Zepzelca zanidatamab and atezolizumab chemotherapy with or without tislelizumab in combination in first-line maintenance therapy for extensive- stage SCLC. HER2-positive locally advanced or metastatic GEA.
Paragraph 52 · 44% changed
Vyxeos + other approved therapies R/R AML or hypomethylating agent failure high-risk MDS that has IDH1 mutation (MD Anderson collaboration study) (ongoing trial)

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A442 words changed in this paragraph; it is 41% similar to last year's version.
In addition, in Pursuant to amendments to our AG agreement with Hikma, effective January 2023, our oxybate products began to face competition from an AG version of high-sodium oxybate pursuant to a settlement agreement 1, 2026, we entered into with an ANDA filer. In July 2023, a volume-limited ANDA filer launched an AG version of high-sodium oxybate. These AG products have negatively impacted and are expected to continue to negatively impact Xyrem and Xywav sales for patients with narcolepsy. Specifically, a wholly owned subsidiary of extended the period during which Hikma launched its AG version of sodium oxybate in January 2023 and Amneal launched its AG version of sodium oxybate in July 2023. Hikma has elected to continue is permitted to sell the Hikma AG product, with royalties product until December 31, 2029. Either we or Hikma may provide notice of intent to be paid to us, for a total of up to four years beginning in January 2024, which election may be terminated by Hikma terminate the amended agreement as early as October 1, 2026, in accordance with the notice provisions in the agreements between the parties. We agreement. Under these amendments, we continue to have the right to receive a meaningful royalty from Hikma on net sales of the Hikma AG product; product throughout the extended Hikma AG period, which royalty rate was fixed for through the second half end of 2023. There was a substantial increase 2025 and then subject to specified reductions as set forth in the royalty rate beginning in January 2024, which will remain fixed for the duration of the agreement's term. our agreement with Hikma. We are also paid for supply of the Hikma AG product and are reimbursed by Hikma for a portion of the services costs associated with the operation of the Xywav and Xyrem REMS, and distribution of the Hikma AG product. We Hikma also granted Hikma maintains a license to launch its own generic sodium oxybate product product, but, if it elects to launch its own generic product, Hikma will no longer have the right to sell the Hikma AG product. In addition, Hikma would need to set up its own REMS (or join an existing REMS operated by another company), which must be open to any other company seeking to commercialize a sodium oxybate product. In our settlements with Amneal, Lupin, and Par, we granted each party the right to sell a limited volume of an The Hikma AG product in the U.S. beginning on July 1, 2023 is expected to continue to negatively impact Xyrem and ending on December 31, 2025, Xywav sales for patients with royalties to be paid to us. Amneal launched its AG version of high-sodium oxybate in July 2023. At this time, Amneal has rights to sell a low-single-digit percentage of historical Xyrem sales over each 6-month sales period. At this time, Lupin and Par have elected not to launch an AG product. AG products will be distributed through the same REMS as Xywav and Xyrem. We also granted each of Amneal, Lupin and Par a license to launch its own generic sodium oxybate product under its ANDA on or after December 31, 2025, or earlier under certain circumstances, including the circumstance where Hikma elects to launch its own generic product. If Amneal, Lupin or Par elects to launch its own generic product under such circumstance, it will no longer have the right to sell an AG product. In addition, any company commercializing a generic version of high-sodium oxybate would need to establish its own REMS, or join an existing REMS operated by another company. narcolepsy.

Source: Item 7, 10-K 0001232524-26-000013 vs Item 7, 10-K 0001232524-25-000011

Risk Factors322 words changed in this paragraph; it is 48% similar to last year's version.
The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, FDA, CMS and related agencies. These actions, presently primarily directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may For example, on September 30, 2025, the current administration announced the first several agreements with major pharmaceutical companies that requires drug manufacturers to offer, through a direct-to-consumer platform, U.S. patients and Medicaid programs prescription drug MFN pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues, in exchange for tariff relief. Other recent actions, for example, include directives (1) directing agencies to reduce agency workforce, rescinding workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a Biden variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing MFN pricing for pharmaceutical products; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the MAHA Commission’s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration executive order tasking the Center recently called on U.S. Congress to enact "The Great Healthcare Plan," to codify and expand MFN pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for Medicare & Medicaid Innovation to consider new over-the-counter purchase, and enact restrictions on PBM payment methodologies, among other things. These actions and healthcare models to limit policies may significantly reduce U.S. drug spending prices, potentially impacting manufacturers’ global pricing strategies and eliminating the Biden administration’s executive order that directed HHS to establish an AI task force profitability, while increasing their operational costs and develop a strategic plan. Additionally, in its compliance risks. In June 2024 decision in Loper Bright, 2024, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give Court’s Loper Bright decision greatly reduced judicial deference to regulatory agencies’ reasonable interpretations of ambiguous federal statutes. The Loper Bright decision agencies, which could result in additional increase successful legal challenges to current federal regulations and guidance issued by federal agencies applicable to affecting our operations, including those issued by FDA. operations. Finally, U.S. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. IRA as well as PBMs. We cannot predict which additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our products, which could have a material adverse effect on our business, financial condition and results of operations.

Source: Item 1A, 10-K 0001232524-26-000013 vs Item 1A, 10-K 0001232524-25-000011

Legal Proceedings167 words changed in this paragraph; it is 43% similar to last year's version.
In March and April 2024, 2025, we received a notice from certain Almaject that it had filed with FDA an ANDA for a generic version of the Epidiolex ANDA Filers that they had each filed Defitelio. The notice from Almaject included a paragraph IV certification regarding one or more newly-issued respect to certain of our patents listed in the FDA’s Orange Book for Epidiolex. Defitelio on the date of the notice. The listed patents relate generally to the Defitelio drug product and its approved use. On July 3, 2024, April 16, 2025, we filed an additional a patent infringement lawsuit against six of the original Epidiolex ANDA Filers with whom we had not previously settled. We filed this lawsuit Almaject in the United States U.S. District Court for the District of New Jersey alleging that, Jersey. The complaint alleges that by filing its ANDA, each Epidiolex ANDA Filer Almaject has infringed the newly-issued patents related to methods certain of treatment using Epidiolex. The suit our Orange Book listed patents, and seeks an order that the effective date of FDA approval of each Epidiolex for the Almaject ANDA Filer’s application shall be on a date no earlier than the expiration of the newly-issued last to expire of the asserted patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Almaject’s ANDA.

Source: Item 3, via Note 13 – Commitments and Contingencies, 10-K 0001232524-26-000013 vs Item 3, via Note 13 – Commitments and Contingencies, 10-K 0001232524-25-000011

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of JAZZ's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 26, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
with each of the ten companies seeking to market a generic version of Epidiolex in the U.S. by granting each of the Epidiolex ANDA Filers a license to manufacture, market, and sell its own generic version of Epidiolex beginning in the very late 2030s, or earlier under certain circumstances, including but not limited to the launch of another generic Epidiolex product or a final decision that all unexpired claims of the Epidiolex patents are not infringed, or are invalid and/or unenforceable. However, these settlements do not prevent other third parties from filing additional ANDAs seeking to market a generic version of Epidiolex in the future. Any such filings could result in additional patent litigation or challenges with respect to Epidiolex and could require substantial financial resources. An adverse outcome in any such litigation, or the entry into additional settlement agreements, could result in the approval and commercialization of generic versions of Epidiolex earlier than anticipated and may have a material adverse effect on our businesses, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
On July 4, 2025, President Trump signed into law the OBBBA, which includes significant changes to Medicaid, Medicare, and the ACA. These reforms are anticipated to decrease federal health care spending by approximately $1 trillion by significantly reducing Medicaid spending and enrollment, making changes to the Medicare program, and altering ACA marketplace enrollment provisions. Such decreases to federal health care spending and loss of health care coverage could reduce access to, and reimbursement for, our products, which could have a negative adverse effect on our revenues.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
MFN pricing models have remained an area of significant interest to the Trump Administration. On July 31, 2025, President Trump issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025 executive order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. The letters also urged these companies to stipulate that they will not offer other developed nations better prices for new drugs than the prices offered for such products in the U.S. The letters called for engagement with FDA and CMS within 60 days to implement these changes and threatened to use “every tool in our arsenal” to address what the letter characterized as “abusive drug pricing practices”. Further, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer Medicaid programs prescription drug MFN pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. As of January 2026, 16 of the 17 pharmaceutical companies that received the July 2025 letters from President Trump have signed agreements with the Trump Administration.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
On November 6, 2025, CMS announced the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model, a model under which participating manufacturers may voluntarily offer MFN pricing to state Medicaid programs for covered outpatient drugs. On December 19, 2025, CMS issued proposed rules to establish the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, two mandatory MFN pricing models impacting Part B drugs and Part D drugs in select geographic areas, respectively. Under the proposed rules, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other economically comparable reference countries, with an initial list of 19 reference countries included in the proposed rule.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
While we are an Irish company headquartered in Dublin, Ireland, we derive the majority of our revenues from sales of our products in the U.S. We conduct business globally and our operations, including third-party suppliers, span numerous countries outside the U.S. In particular, we have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing and development facility in Kent Science Park, U.K. where we produce Epidiolex/Epidyolex, and a manufacturing plant in Villa Guardia, Italy where we produce defibrotide drug substance. In addition, we rely on our supplier in the PRC for the manufacture of Ziihera.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The ongoing trade tensions between the U.S. and other jurisdictions have resulted in multiple rounds of tariffs and anticipated tariffs affecting pharmaceuticals and pharmaceutical ingredients, including finished drug products, manufacturing equipment, and related supplies. Such tariffs may significantly increase our costs for certain products. The Bureau of Industry and Security, U.S. Department of Commerce, has initiated an investigation to determine whether pharmaceutical ingredients, including finished drug product, manufactured outside the U.S. pose a national security risk and should be subject to additional tariffs. Should current tariffs hold or additional tariffs be imposed specifically targeting pharmaceutical imports, such tariffs will result in additional costs on our business, including costs with respect to APIs and other raw materials upon which our business depends and will generally increase our manufacturing costs. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Moreover, other governments have imposed and may continue to impose retaliatory tariffs, trade restrictions or trade barriers on our products, which may impose additional costs and complexity on our business. In addition, the dynamic and unpredictable tariff and trade landscape creates substantial uncertainty and significant planning challenges for our operations. Changes in tariff classifications, country-of-origin requirements or customs procedures can occur with limited notice. This uncertainty complicates our long-term investment decisions regarding manufacturing facilities, supply chain optimization, and R&D locations.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
On April 21, 2025, we completed the acquisition of all the outstanding shares of Chimerix Common Stock. As a result of this, Chimerix became our indirect wholly owned subsidiary. The success of the acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our and Chimerix’s operations and we plan on devoting significant management attention and resources to integrating our business practices and operations with Chimerix’s so that we can fully realize the anticipated benefits of the acquisition. In addition, Modeyso, which we acquired in the acquisition, may not be successful or may require significantly greater resources and investments than originally anticipated. As a result, the anticipated benefits of the acquisition may not be realized fully within the expected timeframe or at all or may take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 71
AddedRisk Factors
intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In December 2025, the European Parliament and the Council of the EU reached a provisional agreement on the revision of the existing EU pharmaceutical legislation, including the pediatric and orphan regulations. Under new legislation, there are some changes to the regulatory exclusivity periods. The provisional agreement is still pending formal approval by the
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
European Parliament and the Council of the EU and subsequent publication in the Official Journal of the EU. Dependent on the final version of the text, the new legislation could impact our ability to secure orphan designation for future products, and would impact the scope and duration of market and orphan exclusivities in the EU. The new legislation could impact our ability to maintain marketing exclusivity for future products in all EU member states if we are unable to meet certain access obligations or if we are unable to supply sufficient quantities of our product in all member states.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
Our products compete, and our product candidates may in the future compete, with currently existing therapies, including other branded products, AG and other generic products, product candidates currently under development by us and others and/or future product candidates, including new molecular and chemical entities that may be safer or more effective or more
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
take longer to realize or cost more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. In this regard, in the third quarter of 2022, we recorded a $133.6 million asset impairment charge as a result of the decision to discontinue the nabiximols program that we acquired as part of our acquisition of GW. In any event, failure to manage effectively our growth through acquisitions or in-licensing transactions could adversely affect our growth prospects, business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Leahy-Smith America Invents Act permits any person, whether they are accused of infringing the patent at issue or not, to challenge the validity of certain patents through a proceeding before the PTAB of the USPTO.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
on October 30, 2024, the District Court issued an order denying our motion for summary judgment and granting Avadel’s and FDA’s cross-motions for summary judgment. We have appealed the matter to the United States Court of Appeals for the District of Columbia Circuit. We cannot predict the timing or ultimate outcome of this litigation or the impact of this litigation on our business, including any potential adverse consequences to, among other things, our reputation, relationships with governmental or regulatory authorities, including FDA. For additional information, see "FDA Litigation" in Note 13, Commitments and Contingencies—Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of this Annual Report on Form 10‑K.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
product that is similar to a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of orphan marketing exclusivity unless we could demonstrate that our product candidate is safer, more effective or otherwise clinically superior to the approved product.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, or otherwise experience significant disruptions of our, our third party vendors’ and/or business partners’ information technology systems or security breaches, including in our remote work environment, such occurrence could adversely affect our
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. Rebates are no longer subject to a cap on the rebate amount, which negatively impacts our rebate liability.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
distribution of our profits or losses between the jurisdictions where we operate and changes to or differences in interpretation of tax laws. For example, our income tax expense for the year ended December 31, 2021, included an expense of $259.9 million arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following enactment of the U.K. Finance Act 2021.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedRisk Factors
Trade In any event, further trade restrictions and export regulations, or increases in tariffs (including tariffs on imports from Europe) and additional taxes, new or increased tariffs, including any further retaliatory measures, can negatively impact end-user demand, could increase our supply chain complexity and our manufacturing costs, decrease our margins, reduce the competitiveness of our products, or restrict our ability to sell our products, provide services or purchase necessary equipment and supplies, any or all of which could have a material and adverse effect on our business, results of operations, or financial condition and, given the nature of our products, relocating the manufacturing supply can be a complex, costly and time-consuming process making it difficult to react quickly to a changing environment. supplies.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, the House of Representatives of the prior Congress (the 118th Congress) passed the BIOSECURE Act, which proposed targeting to ban U.S. government contracts, grants grants, and loans for entities that use from being used towards biotechnology equipment and services produced or services from provided by certain named Chinese biotechnology companies, including WuXi, and potentially other would authorize the U.S. government to name additional Chinese biotechnology companies designated in the future. of concern.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Although FDA has stated, in granting a Citizen Petition we submitted in 2016, that it would not approve any sodium oxybate ANDA referencing Xyrem that does not include the portions of the currently approved Xyrem label related to the DDI patents, we cannot predict whether a future ANDA filer, or a company that files a Section 505(b)(2) application for a drug referencing Xyrem, may pursue regulatory strategies to avoid infringing our DDI patents notwithstanding FDA’s response to the Citizen Petition, or whether any such strategy would be successful.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Regulatory and legislative changes, and judicial rulings relating to the Medicaid Drug Rebate Program and related policies (including coverage expansion), have increased and will continue to increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, Similarly, even though FDA also granted seven-year ODE to Xywav, Xywav in IH, FDA also approved Lumryz and granted Lumryz seven-year ODE ODD based on FDA’s finding the plausible hypothesis that Lumryz makes may be clinically superior to Xywav and Xyrem because Lumryz may provide a major contribution to patient care and is therefore clinically superior to Xywav and Xyrem. care.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In this regard, our ability to maintain oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties as discussed in greater detail below, including: those related to the commercialization of Xywav for the treatment of IH in adults and adoption in that indication; competition from the introduction of AG versions of high-sodium oxybate and branded products, such as Avadel’s Alkermes’ once-nightly dose, high-sodium oxybate branded product Lumryz, Lumryz (acquired through its acquisition of Avadel), for treatment of cataplexy and/or EDS in adults with narcolepsy in the U.S. market, as well as potential future competition from additional AG and generic versions of high-sodium oxybate, including a generic version of high-sodium oxybate from Amneal approved in September 2025, from Ascent approved in November 2025, and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav and Xyrem; Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xyrem and/or Xywav, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
A substantial decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds and would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
While a Phase 3 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC, our inability to confirm its clinical benefit in the first-line setting for patients with HER2-positive BTC could result in the withdrawal of approval of Ziihera, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
While a the Phase 3 ACTION confirmatory trial is ongoing to evaluate zanidatamab Modeyso in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC, H3 K27M-mutant diffuse glioma, our inability to confirm its clinical benefit in the first-line setting for patients with HER2-positive BTC diffuse midline glioma harboring an H3 K27M mutation could result in the withdrawal of approval of Ziihera, Modeyso, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA’s or similar international regulatory body’s requirements for approval, there could be a shortage of the affected products for the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
For example, Furthermore, FDA granted accelerated approval to Zepzelca Modeyso for relapsed SCLC adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy based on data from a Phase 2 trial, which approval is contingent upon verification and description of clinical benefit in a post-marketing clinical trial.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Moreover, if a dispute arises with our employees, consultants, advisors or partners over the ownership of rights to inventions, including jointly developed intellectual property, we could lose patent protection or the confidentiality of our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Because patients, consumers and others may not differentiate other high-sodium oxybate products from our sodium oxybate products or differentiate between the different REMS programs, any negative outcomes, including risks to the public, caused by or otherwise related to a separate high-sodium oxybate REMS, could have a significant negative impact in terms of product liability, our reputation and good will, goodwill, public acceptance of Xywav or Xyrem as a treatment for cataplexy and EDS in narcolepsy or Xywav for the treatment of IH, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which could have a material adverse effect on our business.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
We cannot predict the outcome of these or any potential additional lawsuits; however, if the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
These actions, presently primarily directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
We have periodically increased the price of our products, including Xywav and Xyrem most recently in January 2025, 2026, and there is no guarantee that we will not make similar price adjustments to our products in the future or that price adjustments we have taken or may take in the future will not negatively affect our sales volumes and revenues.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Although we are not directly generally subject to HIPAA, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly receive individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
Drug products approved for medical use by FDA that contain cannabis or cannabis extracts may be controlled substances and and, if so, will be rescheduled to Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Rylaze® (crisantaspase recombinant) A component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL, in adults and pediatric patients 1 year or older who have developed hypersensitivity to September 2022 Canada
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Ziihera is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. In the U.S., Ziihera was granted accelerated approval by FDA in November 2024 and is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) BTC, as detected by an FDA-approved test. Ziihera was launched in December 2024. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 HERIZON-BTC-302 confirmatory trial. In June 2025, the EC granted conditional marketing authorization for Ziihera for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC previously treated with at least one prior line of systemic therapy. In January 2026, Ziihera obtained conditional approval in Canada for the treatment of adults with previously treated, unresectable locally advanced or metastatic HER2-positive (IHC3+) BTC, as monotherapy.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
We completed the Chimerix Acquisition in April 2025 for a total cash consideration of $944.2 million, adding Modeyso, a protease activator of the ClpP that also inhibits DRD2, to our rare oncology portfolio. In August 2025, Modeyso was granted accelerated approval by FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is the first and only treatment option approved by FDA for this ultra-rare and aggressive brain tumor that mainly affects children and young adults. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial. In connection with the approval by FDA of Modeyso in August 2025, we received a rare pediatric disease PRV, which we sold in January 2026 for total cash consideration of $200.0 million of which 50% is attributable to us.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In October 2025, we divested Sativex to CNX Therapeutics, who will assume responsibility for Sativex in all countries it is approved. Our existing partnerships will transition to CNX Therapeutics and it will take responsibility for commercialization in those markets previously owned by us. We will continue to manufacture Sativex during the transition period given the complexity of the product and all external growing partnerships will transition to CNX Therapeutics.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In November 2025, we announced positive top-line results from the pivotal Phase 3 HERIZON-GEA-01 trial of zanidatamab in combination with chemotherapy, with or without tislelizumab, as first-line treatment for adults with HER2-positive locally advanced or metastatic GEA. In January 2026, we presented late-breaking results from the trial at ASCO GI. The investigational arm containing zanidatamab plus tislelizumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival benefit of more than two years of median overall survival. The greater than seven-month improvement in median overall survival represents a 28% reduction in the risk of death versus the control arm. Both investigational arms led to a statistically significant and clinically meaningful median progression-free survival of more than one year, representing a greater than four-month improvement and 35% reduction in the risk of disease progression or death
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Zanidatamab is currently being evaluated in multiple clinical trials as a treatment for patients with HER2-expressing cancers: a Phase 2 DiscovHER-Pan-206 trial evaluating zanidatamab monotherapy in previously-treated patients with various HER2-positive (IHC3+) cancers, a Phase 2 EmpowHER-BC-208 trial to evaluate zanidatamab in patients with HER2-positive neoadjuvant and adjuvant breast cancer, a Phase 3 trial EmpowHER-BC-303 to evaluate zanidatamab plus chemotherapy or trastuzumab plus chemotherapy in patients with HER2-positive breast cancer whose disease has progressed on previous T-DXd treatment, and a Phase 3 confirmatory trial examining zanidatamab in first-line patients with HER2-positive BTC.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In April 2025, we completed the Chimerix Acquisition for $944.2 million in cash, and Chimerix is now our wholly owned subsidiary. The lead clinical asset acquired from Chimerix is Modeyso, a novel first-in-class small molecule that is a protease activator of the ClpP that also inhibits DRD2. In August 2025, Modeyso was granted accelerated approval by FDA for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is the first and only treatment option approved by FDA for this ultra-rare and aggressive brain tumor that mainly affects children and young adults. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial. The ongoing Phase 3 ACTION trial is evaluating Modeyso in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending this treatment option into the front-line setting.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In November 2025, we initiated a Phase 1b trial evaluating Epidiolex as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of Epidiolex on health outcome endpoints in early line and refractory participants with focal-onset seizures.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
•Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our patients across our product portfolio, which focuses on neuroscience and oncology medicines;
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Ziihera is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. In the U.S., Ziihera
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
was approved by FDA in November 2024 and is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Defitelio is the first and only approved treatment for patients with VOD, sVOD, or VOD with renal or pulmonary dysfunction following HSCT by regulatory authorities in the U.S., Europe, Japan and other markets. Utilization of Defitelio is in part driven by evolving treatment practices in HSCT, and we are continuing to educate healthcare professionals on the clinical profile of Defitelio and its role in treating VOD and/or severe VOD following HSCT.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Vyxeos is a treatment for adults with newly-diagnosed t-AML, or AML-MRC. In March 2021, FDA approved a revised label to include a new indication to treat newly-diagnosed t-AML, or AML-MRC, in pediatric patients aged one year and older. We continue to expand into new markets internationally as the product receives approvals and reimbursement in relevant markets. In the U.S., with ongoing trends towards lower-intensity treatments and away from intensive chemotherapy regimens for AML, we have seen increasing competition from other therapeutic options.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
In addition, we have an ongoing Phase 4 observational study to collect real world safety and outcome data in adult Zepzelca monotherapy patients with SCLC who progress on or after prior platinum-containing chemotherapy. Preliminary findings from this study presented at the 2024 World Conference on Lung Cancer demonstrated Zepzelca provided clinical
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedMD&A
Department of Health and Human Services Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes The IRA also made several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, that could negatively affect our business and financial condition.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Department of Health and Human Services For example, the IRA, among other things, requires the HHS Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026, 2026 and penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation, and makes several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, that could negatively affect our business and financial condition. inflation.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our contingent obligations to third parties, in the form of development, regulatory and sales-based milestone payments, as of December 31, 2024 2025 included $1,362.5 million under our license and collaboration agreement with Zymeworks, $1,255.0 million under our global license and collaboration agreement with Werewolf, $1,090.0 million under our license agreement with Sumitomo, $1,065.0 million under our asset purchase agreements with Redx, $992.5 million under our global license agreement with Saniona, $752.5 million under our license and collaboration agreement with Autifony, $581.0 $531.0 million under our amended license agreement with PharmaMar, $375.0 million under the asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., $260.0 million in connection with our acquisition of Cavion, $155.5 million under our license agreement with Ligand, and $492.4 million related to other agreements.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
If we are unable to obtain further share issuance and pre-emption authorities from our shareholders in the future, or otherwise continue to be limited by the terms of new share issuance and pre-emption authorities approved by our shareholders in the future, our ability to use our unissued share capital to fund in-licensing, acquisition or other business opportunities, or to otherwise raise capital, including at the time we are required to make repurchases of the 2026 Notes, the 2030 Notes and/or the Secured Notes, are required to repay outstanding amounts under the Amended Credit Agreement, or pay cash upon exchange of the 2026 Notes or the 2030 Notes, could likewise be adversely affected.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
For 2025, 2026, we expect that our research and development R&D expenses will decrease increase compared to 2024, 2025, primarily driven by a reduction an increase in clinical studies and outside services service costs relating to JZP385 zanidatamab, for both ongoing and continued portfolio prioritization. new studies, dordaviprone, due to the inclusion of a full year’s expenses, and preclinical and early clinical programs.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In May 2022, we announced that we had entered into a licensing agreement with Sumitomo to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for JZP441, also known as DSP-0187, JZP441 is a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, IH and other sleep disorders.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We Under these amendments, we continue to have the right to receive a meaningful royalty from Hikma on net sales of the Hikma AG product; product throughout the extended Hikma AG period, which royalty rate was fixed for through the second half end of 2023. 2025 and then subject to specified reductions as set forth in our agreement with Hikma.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The holders of the 2030 Notes have the ability to require us to repurchase all or a portion of their 2030 Notes for cash at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date in the event we undergo a fundamental change (as defined in the indenture related to the 2030 Notes), such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In April 2022, August 2025, we announced that we had entered into a licensing and collaboration global license agreement with Werewolf Saniona to acquire obtain exclusive global development and commercialization worldwide rights to Werewolf's investigational WTX-613, develop SAN2355, now referred to as JZP898. JZP053, for epilepsy and other potential indications.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our commercial efforts are focused on educating patients and physicians about on the lifelong impact strength of high sodium intake, and how clinical evidence that supports the use of Xywav enables them to address what is a modifiable risk factor for cardiovascular morbidity. treating narcolepsy and IH.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Xywav Vyxeos product sales increased by 10% in 2024 compared to 2023, primarily due to increased sales volumes of 16% and, to a lesser extent, a higher selling price, volumes, partially offset by higher gross a lower average selling price due to net deductions. regional mix.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
These You should review the risks and uncertainties described in “Risk Factors” in Part I, Item 1A in this Annual Report on Form 10‑K for a discussion of important factors that could cause actual results to differ materially from those projected in forward-looking statements contained in this report or implied by past results and trends.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
We cannot predict the outcome of these or any potential additional lawsuits; however, if the plaintiffs were to be successful in their claims against us, they may be entitled to injunctive relief or we may be required to pay significant monetary damages.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
Cost of product sales increased in 2024 compared to 2023, primarily due to increased inventory provisions and changes in product mix, offset by a decrease in the fair value step-up expense, of $16.4 million.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
Finite-lived intangible assets consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from seven four to sixteen years.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/JAZZ/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.